Asian Activities Report for December 14, 2011: Coach (NYSE:COH) (HKG:6388) Opens First Official Online Flagship Store in China on Taobao Mall

Sydney, Dec 14, 2011 AEST (ABN Newswire) - Coach, Inc. (NYSE:COH) (HKG:6388) has opened its first official online store in China on Taobao Mall (coach.tmall.com), a leading business-to-consumer shopping website under Alibaba Group. In celebration of Coach's 70th anniversary, the online store will open for a month from December 12, 2011 to January 15, 2012, offering a range of fashion accessories and gifts for women and men, including handbags, accessories and lifestyle products, many of which are limited editions, best sellers, and exclusive items available only on Taobao Mall.

Japan-based global IT giant NTT Data Corporation (TYO:9613) has opened a childcare centre, named "Egg Garden" at its headquarter in Toyosu, Koto-ku, Tokyo, Japan. Egg Garden provides day care services to all NTT employees who are unable to send their babies to nurseries. The Company is hoping that, with the service, employees who are trying to juggle their job with parental obligations can go to work without worrying about their babies.

Shiseido (TYO:4911) has announced its intent to sell bareMinerals makeup products in Brazil. Starting in May, product sales will be carried out through e-commerce and retail stores, including standalone bareMinerals boutiques. This will be the first time that bareMinerals has been marketed throughout South America, and Shiseido expects to have over 100 stores in Brazil selling bareMinerals products over the next five years.

Astellas Pharma Inc. (TYO:4503) and Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) announced that the European Commission has granted a marketing authorisation for DIFICLIR(TM) tablets for the treatment of adults aged 18 years and older with Clostridium difficile infections (CDI) in the European Union. Treatment for CDI has changed little in the past 20 years, even though the disease has a major impact on patients' health and quality of life and is potentially fatal. The EU approval of DIFICLIR is therefore an important advance for patients suffering from CDI.

Contact

Qiubei Fu Asia Business News Tel: +61-2-9247-4344 http://www.abnnewswire.net